Amgen Inc. (AMGN)
3 Fabulous Growth Stocks to Buy and Hold Forever
Investors have been on a roller coaster ride for the past four years. One of the longest bull markets in history was brought to a screeching halt by the global pandemic.
7 Biotech Stocks to Keep on Your Clinical Radar
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
Amgen (AMGN) concluded the recent trading session at $331.29, signifying a +0.1% move from its prior day's close.
3 Biotech Stocks to Buy Now: Q3 Edition
Biotech stocks to buy can be an interesting sector for investors. They can provide massive gains following positive news regarding clinical trials or FDA approvals.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What Is the Dividend Payout for Amgen Stock?
Amgen currently continues its pattern of quarterly dividend increases. Furthermore, Amgen demonstrated product-sales growth in the first quarter.
Amgen (AMGN) Rises Higher Than Market: Key Facts
Amgen (AMGN) reachead $330.83 at the closing of the latest trading day, reflecting a +1.77% change compared to its last close.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
‘Crash proof' your portfolio with these 10 stocks and 3 ETFs
You don't get upset for having homeowner's insurance but your house doesn't burn down. The same principle should apply to investors who insure their stock portfolios against a crash.
3 Dividend Stocks Crushing the S&P 500 With 30%+ Annual Total Returns
With technology-driven growth stocks propelling the S&P 500 to new heights, dividend stocks have often found themselves playing catch-up. Yet, even in this market environment, some dividend-paying companies have managed not only to keep pace, but also beat the index by a significant margin.
Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Amgen shares have outperformed IBB by over 40% in the past year, driven higher by a major surge post-earnings in May. With a current price-to-earnings multiple in the mid-teens, I assert that solid and consistent EPS growth ahead warrants a higher valuation. AMGN's chart is also impressive, with a long-term uptrend in place.
